{"name":"Sangart","slug":"sangart","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Hemospan (MP4OX)","genericName":"Hemospan (MP4OX)","slug":"hemospan-mp4ox","indication":"Acute blood loss / hemorrhagic shock requiring oxygen therapeutic support","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Voluven (HES 130/0.4)","genericName":"Voluven (HES 130/0.4)","slug":"voluven-hes-130-0-4","indication":"Volume expansion in adults and children with hypovolemia due to trauma, surgery, or burns","status":"phase_3"}]}],"pipeline":[{"name":"Hemospan (MP4OX)","genericName":"Hemospan (MP4OX)","slug":"hemospan-mp4ox","phase":"phase_3","mechanism":"Hemospan is a pegylated hemoglobin-based oxygen carrier that binds and transports oxygen to tissues, functioning as a blood substitute or oxygen therapeutic.","indications":["Acute blood loss / hemorrhagic shock requiring oxygen therapeutic support","Severe anemia in perioperative or trauma settings"],"catalyst":""},{"name":"Voluven (HES 130/0.4)","genericName":"Voluven (HES 130/0.4)","slug":"voluven-hes-130-0-4","phase":"phase_3","mechanism":"Voluven (HES 130/0.4) is a colloid volume expander used to increase blood volume.","indications":["Volume expansion in adults and children with hypovolemia due to trauma, surgery, or burns"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPZ1I0MW1aQ3NUWU5JZExNVkNvYU5yU2liZ05hOWNQbjF3U2Z0cUFsLS0yQU5SbVdpamxCSG4xVmhTcjJ0S2ZVMnJKWmlBUVh2Um1lWlZiNmpuelloVWR5LTBob3p0ZFVBaHpiMFYweWxNMFg0R3J3U2s4Nl9SWm5rOEFPV1hEWU5pQklOTmdR?oc=5","date":"2023-09-15","type":"pipeline","source":"citybiz","summary":"Deep Genomics Appoints Brian O’Callaghan as CEO - citybiz","headline":"Deep Genomics Appoints Brian O’Callaghan as CEO","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}